SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to anticipation surrounding its upcoming Investor Day, with investors closely watching for updates on the company's technical roadmap, 2026 financial guidance, and recent integration of the SkyWater Technology acquisition. Sentiment remains divided, as some traders highlight the company's aggressive growth strategy while others express skepticism regarding its valuation and reliance on acquisitions.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm shares are trending following the announcement of a multi-generational collaboration with Amazon to develop customized silicon and optical connectivity solutions for AI data center infrastructure. While the partnership has generated optimism, market focus remains divided as traders react to the company's recent earnings report, margin pressures, and the broader semiconductor sector's volatility.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are gaining momentum ahead of the company's upcoming earnings report, driven by optimistic analyst target increases and excitement surrounding its AI infrastructure positioning. Traders are debating the sustainability of the stock's recent rally, with many anticipating a significant move following the results while weighing the risks of volatility and potential short squeezes.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to the company securing a $100 million U.S. Department of Commerce funding agreement under the CHIPS Act. While some traders view the government backing as a major catalyst for quantum computing R&D, community sentiment remains mixed with debates regarding the stock's valuation, insider selling, and potential for a short squeeze.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trading lower following the failure of a Phase 3 trial for a competitor's DM1 drug, which has fueled speculation among traders about the potential read-through risk for the company's own clinical programs and overall pipeline viability. While some investors view the sell-off as an excessive knee-jerk reaction driven by algorithmic selling and are looking for buying opportunities, others remain cautious regarding the implications of the competitor's failure for the broader space.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently receiving significant attention as investors debate its valuation near 52-week lows, with many traders viewing it as a long-term blue-chip value opportunity while others highlight concerns over weak consumer spending and market sentiment. The discussion is heavily divided between those accumulating shares for dividends and long-term recovery and skeptics who emphasize continued technical selling pressure and macro-related headwinds.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as traders speculate on a potential short squeeze and a technical breakout, driven by the company's progress toward commercializing its CRISPR-based HAE therapy. While some investors remain cautious about cash runway and competitive pressures, others view the stock as undervalued, pointing to institutional accumulation and upcoming regulatory milestones as catalysts for a potential re-rating.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending following an escalation in the conflict between the U.S. and Iran, triggered by new U.S. military strikes on Iranian assets near the Strait of Hormuz. While some traders are betting on a continued surge in prices due to supply disruption fears, others argue that market reaction remains speculative and anticipate potential de-escalation or price volatility.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as traders react to the company finalizing a definitive agreement for up to $100 million in CHIPS and Science Act funding from the U.S. Department of Commerce. While some investors see this government support as a key validation of the company's technology, others remain focused on the sector's long-term commercialization challenges, ongoing stock price volatility, and recent leadership changes.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

The community is debating the stock's long-term value and buyout potential, with many traders expressing frustration over stagnant price action and low volume. While some investors remain optimistic about future pipeline catalysts and Orladeyo's performance, others are heavily criticizing management and speculating on potential M&A activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AKYA 11:45 AM EDT, 05/21/2025 (MT Newswires) -- Akoya Biosciences(AKYA) said in a Wednesday filing that it received an unsolicited acquisition proposal from an undisclosed third party, which offered $1.40 in cash for each Akoya common share.

StockTwits Web

Akoya Biosciences Inc

 11:45 AM EDT, 05/21/2025 (MT Newswires) -- Akoya Biosciences(AKYA) said in a Wednesday filing that it received an unsolicited acquisition proposal from an undisclosed third party, which offered $1.40 in cash for each Akoya common share.